市场调查报告书
商品编码
1373361
胰岛素输送设备市场规模 - 按产品(胰岛素帮浦、胰岛素笔、胰岛素笔针头、胰岛素喷射注射器、胰岛素注射器)、最终用途和全球预测,2023 - 2032 年Insulin Delivery Devices Market Size - By Product (Insulin Pumps, Insulin Pens, Insulin Pen Needles, Insulin Jet Injectors, Insulin Syringes), By End-use & Global Forecast, 2023 - 2032 |
由于人们对家庭医疗保健解决方案的偏好日益增加,加上易于使用的设备不断进步,胰岛素输送设备市场规模预计从 2023 年到 2032 年将以 10.6% 的复合年增长率扩大。
人们越来越重视以患者为中心的护理以及在家中管理慢性疾病的便利性,这使得用户友好型便携式胰岛素输送设备的采用激增,使患者能够自行注射胰岛素。此外,产业参与者正在对策略性措施进行大量投资,以促进远端监控和远距医疗服务的新进步。例如,2023 年5 月,美敦力公司收购了EOFlow Co. Ltd.,该公司是EOPatch (R) 设备的生产商,该设备是一种无管、可穿戴、完全一次性的胰岛素输送系统,以扩大其能力,以满足糖尿病患者更复杂的需求。
胰岛素输送设备产业分为产品、最终用途和地区。
胰岛素笔产品领域的市场份额预计将在 2023 年至 2032 年期间获得显着增长,因为其用户友好且方便的功能可为患者提供高效且谨慎的胰岛素注射方法。具有整合剂量追踪和连接功能的智慧胰岛素笔开发的技术进步激增,将进一步增加产品需求。例如,2022 年12 月,Biocorp 获得了FDA 510(k) 批准,将其Mallya 智慧医疗设备商业化,该设备用于连接胰岛素笔,自动收集和记录重要的治疗信息,以便传输到专用数位应用程式。
预计在 2023 年至 2032 年间,胰岛素输送设备产业将从医院和诊所终端使用领域开始成长。医院和诊所是糖尿病管理的主要中心,进一步需要使用先进的胰岛素输送设备来满足不同的病患需求。全球糖尿病发生率不断上升,导致医疗机构对高效、可靠的胰岛素输送解决方案的需求增加,也推动了该领域的成长。
从地区来看,欧洲胰岛素输送设备产业在2022 年呈现显着成长,预计在2023 年至2032 年期间将实现强劲的复合年增长率,这主要得益于糖尿病盛行率不断上升、强大的医疗基础设施以及积极主动的糖尿病管理方法。此外,政府的支持性政策和对改善患者治疗结果的日益关注正在提高该地区糖尿病护理的质量,从而展现出该行业利润丰厚的增长前景。例如,2023年6月,Insulet公司宣布在英国推出Omnipod 5自动胰岛素输送系统,以减轻两岁及以上第1型糖尿病患者的负担并提高生活品质。
Insulin Delivery Devices Market size is anticipated to expand at 10.6% CAGR from 2023 to 2032, driven by the increasing preference for home-based healthcare solutions coupled with the rising advancements in easy-to-use devices.
The rising emphasis on patient-centric care and the convenience of managing chronic diseases at home is surging the adoption of user-friendly and portable insulin delivery devices for enabling patients to self-administer insulin. Moreover, industry participants are making massive investments in strategic initiatives for new advancements for facilitating remote monitoring and telemedicine services. For instance, in May 2023, Medtronic plc acquired EOFlow Co. Ltd., the producer of the EOPatch® device, a tubeless, wearable, and entirely disposable insulin delivery system, for broadening its capacity to meet the more complex needs of diabetics.
The insulin delivery devices industry is segmented into product, end-use, and region.
The market share from the insulin pens product segment is anticipated to gain significant traction from 2023-2032 due to its user-friendly and convenient features for offering patients an efficient and discreet method for insulin administration. The surge in technological advancements for the development of smart insulin pens with integrated dose tracking and connectivity features will further augment the product demand. For instance, in December 2022, Biocorp acquired the FDA 510(k) approval to commercialize its Mallya smart medical device for connecting to insulin pens to automatically gather and record important treatment information for transmission to dedicated digital application.
Insulin delivery devices industry is projected to grow from the hospitals & clinics end-use segment between 2023 and 2032. Hospitals and clinics serve as primary hubs for diabetes management, further necessitating the usage of advanced insulin delivery devices to cater to diverse patient needs. The rising prevalence of diabetes cases worldwide leading to the heightened demand for efficient and reliable insulin delivery solutions in healthcare facilities is also propelling the segment growth.
Regionally, the Europe insulin delivery devices industry exhibited significant growth in 2022 and is estimated to record robust CAGR from 2023-2032, driven by the increasing prevalence of diabetes, strong healthcare infrastructure, and the proactive approach to diabetes management. Additionally, supportive government policies and the increasing focus on improving patient outcomes are enhancing the quality of diabetes care in the region, thereby demonstrating lucrative growth prospects for the industry. For instance, in June 2023, Insulet Corporation announced the launch of its Omnipod 5 Automated Insulin Delivery System in the U.K. to ease the burden and improve the quality of life for type 1 diabetic patients aged two years and above.